

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION  
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [001-37797](#)

OMB APPROVAL	
OMB Number:	3235-0080
Expires:	December 31, 2014
Estimated average burden hours per response:	1.7

Issuer: <a href="#">INNOVATE BIOPHARMACEUTICALS, INC.</a>
Exchange: <a href="#">The Nasdaq Stock Market LLC</a>

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: <a href="#">2655 Park Center Drive, Unit C</a> <a href="#">Simi Valley CALIFORNIA 93065</a>
Telephone number: <a href="#">8,059,554,190</a>

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

<a href="#">Warrant</a>
-------------------------

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. <sup>1</sup>

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, [The Nasdaq Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

<a href="#">2018-04-19</a>	By	<a href="#">Amy Horton</a>	<a href="#">Hearings Advisor</a>
Date		Name	Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, April 19, 2018, Innovate Biopharmaceuticals, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the warrant of Innovate Biopharmaceuticals, Inc. (the Company), effective at the opening of the trading session on April 30, 2018. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(b)(1). The Company was notified of the Staffs determination on October 19, 2017. The Company appealed the determination to a Hearing Panel. Upon review of the information provided by the Company, the Panel issued a decision dated December 11, 2017, granting the Company continued listing pursuant to an exception that included several milestones that the Company was required to meet, towards the goal of regaining compliance with Listing Rules 5550(b)(1), 5550(a)(2), 5555(a)(2) and 5620(a). The Company met the exception milestones for its common stock, however, the Company was unable to meet the exception milestones for the warrant. On February 27, 2018, the Panel issued a final compliance determination for the common stock and notified the Company that trading in the Companys warrant would be suspended on March 5, 2018. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Companys warrant became final on March 5, 2018.